Kakuji Torigoe
Vertex Pharmaceuticals
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kakuji Torigoe.
Journal of Biological Chemistry | 1997
Kakuji Torigoe; Shimpei Ushio; Takanori Okura; Susumu Kobayashi; Madoka Taniai; Toshio Kunikata; Tadatoshi Murakami; Osamu Sanou; Hirotada Kojima; Mitsukiyo Fujii; Tsunetaka Ohta; Masao Ikeda; Hakuo Ikegami; Masashi Kurimoto
Interleukin (IL)-18 was identified as a molecule that induces IFN-γ production and enhances NK cell cytotoxicity. In this paper, we report upon the purification and characterization of human IL-18 receptor (hIL-18R). We selected the Hodgkin’s disease cell line, L428, as the most strongly hIL-18R-expressing cell line based on the results of binding assays. This binding was inhibited by IL-18 but not by IL-1β. The dissociation constant (K d ) of125I-IL-18 binding to L428 cells was about 18.5 nm, with 18,000 binding sites/cell. After immunizing mice with L428 cells and cloning, a single monoclonal antibody (mAb) against hIL-18R was obtained (mAb 117-10C). Sequentially, hIL-18R was purified from 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS)-extracted L428 cells by wheat germ lectin-Sepharose 4B chromatography and mAb 117-10C-Sepharose chromatography. The internal amino acid sequences of hIL-18R all matched those of human IL-1 receptor-related protein (IL-1Rrp), the ligand of which was unknown to date. When expressed in COS-1 cells, the cDNA of IL-1Rrp conferred IL-18 binding properties on the cells and the capacity for signal transduction. From these results, we conclude that a functional IL-18 receptor component is IL-1Rrp.
Journal of Biological Chemistry | 1997
Kenji Akita; Takashi Ohtsuki; Yoshiyuki Nukada; Tadao Tanimoto; Motoshi Namba; Takanori Okura; Rohko Takakura-Yamamoto; Kakuji Torigoe; Yong Gu; Michael S.-S. Su; Mitsukiyo Fujii; Michiyo Satoh-Itoh; Kouzo Yamamoto; Keizo Kohno; Masao Ikeda; Masashi Kurimoto
Recently, human interleukin 18 (hIL-18) cDNA was cloned, and the recombinant protein with a tentatively assigned NH2-terminal amino acid sequence was generated. However, natural hIL-18 has not yet been isolated, and its cellular processing is therefore still unclear. To clarify this, we purified natural hIL-18 from the cytosolic extract of monocytic THP.1 cells. Natural hIL-18 exhibited a molecular mass of 18.2 kDa, and the NH2-terminal amino acid was Tyr37. Biological activities of the purified protein were identical to those of recombinant hIL-18 with respect to the enhancement of natural killer cell cytotoxicity and interferon-γ production by human peripheral blood mononuclear cells. We also found two precursor hIL-18 (prohIL-18)-processing activities in the cytosol of THP.1 cells. These activities were blocked separately by the caspase inhibitors Ac-YVAD-CHO and Ac-DEVD-CHO. Further analyses of the partially purified enzymes revealed that one is caspase-1, which cleaves prohIL-18 at the Asp36-Tyr37 site to generate the mature hIL-18, and the other is caspase-3, which cleaves both precursor and mature hIL-18 at Asp71-Ser72 and Asp76-Asn77 to generate biologically inactive products. These results suggest that the production and processing of natural hIL-18 are regulated by two processing enzymes, caspase-1 and caspase-3, in THP.1 cells.
Cancer Immunology, Immunotherapy | 1997
Mark Micallef; Kenshi Yoshida; Sachiko Kawai; Toshiharu Hanaya; Keizo Kohno; Shigeyuki Arai; Tadao Tanimoto; Kakuji Torigoe; Mitsukiyo Fujii; Masao Ikeda; Masashi Kurimoto
Abstract Interferon-γ-inducing factor/interleukin-18 is a novel cytokine that reportedly augments natural killer (NK) activity in human and mouse peripheral blood mononuclear cell cultures in vitro and has recently been designated IL-18. In this study, IL-18 exhibited significant antitumor effects in BALB/c mice challenged intraperitoneally (i.p.) with syngeneic Meth A sarcoma when administered i.p. on days 1, 2 and 3 after challenge. Intravenous (i.v.) administration also induced antitumor effects in the tumor-bearing mice; however, subcutaneous (s.c.) administration did not. When mice were twice pretreated with 1 μg IL-18 3 days and 6 h before tumor challenge, all mice survived whereas control mice died within 3 weeks of challenge. Inhibitory effects on Meth A cell growth in vitro were not observed with either IL-18 or interferon γ. The effects of IL-18 pretreatment were abrogated by abolition of NK activity after mice had been injected with anti-asialo GM1 antibody 48 h before and, 24 h and 72 h after tumor challenge. Mice pretreated with IL-18 and surviving tumor challenge resisted rechallenge with Meth A cells but could not reject Ehrlich ascites carcinoma, and spleen cells from the resistant mice, but not control mice, exhibited cytotoxic activity against Meth A cells in vitro after restimulation with mitomycin C-treated Meth A cells for 5 days. The effector cells in the spleen cell preparations from resistant mice appear to be CD4+ cells because cytolytic activity was significantly inhibited after depletion of this subset by monoclonal antibodies and complement. In conclusion, IL-18 exhibits in vivo immunologically (primarily NK) mediated antitumor effects in mice challenged with syngeneic Meth A sarcoma and induces immunological memory and the generation of cytotoxic CD4+ cells.
FEBS Letters | 1999
Yasushi Aizawa; Kenji Akita; Madoka Taniai; Kakuji Torigoe; Tetsuya Mori; Yoshihiro Nishida; Shimpei Ushio; Yoshiyuki Nukada; Tadao Tanimoto; Hakuo Ikegami; Masao Ikeda; Masashi Kurimoto
Interleukin‐18 binding protein is a novel glycoprotein that we successfully cloned and expressed. First, murine interleukin‐18 binding protein was purified from the sera of mice with endotoxin shock using ligand affinity chromatography. The murine interleukin‐18 binding protein cDNA was cloned after RT‐PCR using mixed primer pair sequences based on partial murine interleukin‐18 binding protein amino acid sequence analysis. Subsequently, human interleukin‐18 binding protein cDNA was cloned from cDNA libraries of normal human liver using murine interleukin‐18 binding protein cDNA as a probe. Next, we transiently expressed recombinant human and murine interleukin‐18 binding proteins in COS‐1 cells and purified them from culture supernatants. Both recombinant interleukin‐18 binding proteins did not exhibit species specificity and prevented interleukin‐18 binding to its receptor. In addition, they inhibited interleukine‐18 dependent IFN‐γ production from KG‐1 cells effectively. These results suggest that the interleukin‐18 binding protein may possess interleukine‐18 antagonist activity.
FEBS Letters | 1994
Motoshi Namba; Mayumi Kurose; Kakuji Torigoe; Katsuhiko Hino; Yoshifumi Taniguchi; Shigeharu Fukuda; Mitsuko Usui; Masashi Kurimoto
Cloning of a cDNA from Cry j II, the second major allergen from Japanese cedar (Cryptomeria japonica) pollen, is described. An isolated Cry j II cDNA contained an open reading frame coding for 514 amino acid residues. The mature Cry j II protein consisted of 388 amino acid residues (R46—S433). According to a homology analysis, no amino acid sequence homology was observed between Cry j II and Cry j I, another major allergen. But Cry j II showed homology with polygalacturonase (PG) derived from tomato (40% identity) at the amino acid level. The sequence information can potentially be used to devise an effective course of immunotherapy for Japanese cedar pollinosis.
Cancer Immunology, Immunotherapy | 1999
Mark Micallef; Tadao Tanimoto; Kakuji Torigoe; Yoshihiro Nishida; Keizo Kohno; Hakuo Ikegami; Masashi Kurimoto
Abstract Interleukin-18 (IL-18) enhances interferon γ (IFNγ) production and natural killer (NK) cell activity, and elicits protective antitumor effects in vivo. IL-18 and IL-12 synergistically augment IFNγ production reportedly because IL-12 enhances IL-18 receptor (IL-18R) expression. We now show that IL-18 also synergizes with IL-10 to augment murine splenic NK activity against Yac-1 cells in a standard 4-h chromium-release assay, but IFNγ production is only slightly enhanced. This pattern of NK activity was also observed with severe combined immunodeficient (SCID) mouse spleen cells indicating that the cytokines were not acting on T or B cells. The cytokines had no priming activity on the spleen cells and, when cells were left unstimulated for 24 h in culture, little NK activity was induced when IL-18 was added for the next 24 h. The reverse transcriptase/polymerase chain reaction revealed that IL-18 receptor (IL-18R) mRNA was expressed early during in vitro spleen cell culture but none was expressed after culture for 24 h regardless of the stimulus. Binding of 125I-labeled IL-18 revealed that exposure to IL-10 only slightly increased IL-18R expression. Expression of perforin mRNA was constitutive and was unaffected by the cytokines; however, Fas ligand (FasL) mRNA expression was strong in cultures with IL-18 alone or combined with IL-10. When Fas-expressing cells and their parental cells were used as targets, weak Fas-mediated cytolytic activity was observed after exposure to IL-18, and this was further enhanced by combination with IL-10. Finally, the augmentation of NK activity was abrogated by the inhibitor concanamycin A, indicating that the enhanced NK activity is perforin-dependent.
Japanese Journal of Cancer Research | 1988
Shunsaku Ando; Tsunetaka Ohta; Tadao Tanimoto; Osamu Sano; Hiroshi Yamauchi; Osamu Andoh; Kakuji Torigoe; Masashi Kurimoto
A human myelomonocytic cell line, HBL‐38 cells, propagated in vivo, spontaneously produced interferon (IFN)‐γ and IFN‐α. Whereas hemmagglutinating virus of Japan (HVJ) enhanced the production of IFN‐α, bacterial lipopolysaccharide (LPS) markedly enhanced the production of IFN‐γ. LPS could be replaced with lipid A. Furthermore, the enahancement of production of IFN‐γ by LPS was completely abolished by polymixin B. IFN‐γ derived from LPS‐stimulated HBL‐38 cells was purified to homogeneity and characterized. The apparent molecular weight, subspecies composition, amino acid sequence and glycosylated sites were in agreement with those of the product of normal human peripheral blood lymphocytes (PBL). These results indicate that the myelomonocytic HBL‐38 cells, not a T‐cell line, can also produce IFN‐γ identical to the product of normal human PBL.
In Vitro Cellular & Developmental Biology – Animal | 1998
Kazuo Fushimi; Kakuji Torigoe; Hiroshi Yamauchi; Shouji Furusako; Masashi Kurimoto; Masayoshi Namba
SummaryTo develop a new gene therapy model for cancer, a clonal cell line (KMST-6/TNF) which produces human tumor necrosis factor α (hTNF-α) has been developed by introducing hTNF-α cDNA into a human immortal fibroblast cell line (KMST-6). The conditioned medium (CM) of KMST-6/TNF cells inhibited the growth of various malignant human cell lines, but not that of normal human fibroblasts. Although the growth inhibitory effects of KMST-6/TNF CM were neutralized to a considerable degree by anti-TNF-α antibody, its inhibitory effects were more marked than the purified human natural TNF-α itself in the same units, suggesting that KMST-6/TNF CM contains some growth inhibitory substances other than TNF-α. However, interferons α, β, and γ were undetectable in the KMST-6/TNF CM.
Nature | 1995
Haruki Okamura; Hiroko Tsutsui; Toshinori Komatsu; Masuo Yutsudo; Akira Hakura; Tadao Tanimoto; Kakuji Torigoe; Takanori Okura; Yoshiyuki Nukada; Kazuko Hattori; Kenji Akita; Motoshi Namba; Fujimi Tanabe; Kaori Konishi; Shigeharu Fukuda; Masashi Kurimoto
European Journal of Immunology | 1996
Mark Micallef; Takashi Ohtsuki; Keizo Kohno; Fujimi Tanabe; Shimpei Ushio; Motoshi Namba; Tadao Tanimoto; Kakuji Torigoe; Mitsukiyo Fujii; Masao Ikeda; Shigeharu Fukuda; Masashi Kurimoto